Markets

Addicted to IPOs: Braeburn Pharmaceuticals files for a $150 million IPO

Braeburn Pharmaceuticals, a commercial stage pharmaceutical offering implantable treatment for opioid addiction, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

The Princeton, NJ-based company was founded in 59 and booked $43 thousand in sales for the 12 months ended September 30, 2016. It plans to list on the Nasdaq under the symbol BBRX. J.P. Morgan, BofA Merrill Lynch and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Addicted to IPOs: Braeburn Pharmaceuticals files for a $150 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos